Holen Sie sich die Stockscreener-App
31.22
2.22%
0.75
Crinetics Pharmaceuticals Inc Aktie (CRNX) Neueste Nachrichten
Crinetics Pharmaceuticals (CRNX) Gets Initiated With a Hold Rating at Goldman Sachs - MSN
What drives Crinetics Pharmaceuticals Inc. stock priceRapidly growing investment returns - jammulinksnews.com
What analysts say about Crinetics Pharmaceuticals Inc. stockStrong return on assets - jammulinksnews.com
Crinetics’ TSHR antagonist demonstrates efficacy in thyroid autoimmune disorders - BioWorld MedTech
Crinetics stock rating reiterated by Piper Sandler ahead of PALSONIFY PDUFA - Investing.com Canada
H.C. Wainwright reiterates Buy rating on Crinetics stock at $81 price target - Investing.com UK
Crinetics Pharmaceuticals’ Palsonify Gains Positive Endorsement for Acromegaly Treatment with Promising Pipeline Expansion - TipRanks
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Purchased by Arizona State Retirement System - Defense World
Is Crinetics Pharmaceuticals Inc. a good long term investmentPowerful growth strategies - PrintWeekIndia
The week in pharma: action, reaction and insight – week to July 18 - The Pharma Letter
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Purchased by Xponance Inc. - Defense World
Crinetics Pharmaceuticals Inc. Stock Analysis and ForecastHigh-velocity gains - jammulinksnews.com
Crinetics Pharmaceuticals’ SWOT analysis: promising pipeline drives stock outlook - Investing.com
Crinetics stock maintains Buy rating at Jones Trading on positive ENDO’25 data - Investing.com Canada
How Crinetics Pharmaceuticals Inc. stock performs during market volatilityFree Signals Group - Newser
12 Oversold NASDAQ Stocks to Buy Now - Insider Monkey
what makes crinetics pharmaceuticals inc. stock price move sharplySafer Investing With Bigger Upside - Newser
What makes Crinetics Pharmaceuticals Inc. stock price move sharplyFree Wealth-Building Investment Strategies - Newser
Why Crinetics Pharmaceuticals Inc. stock attracts strong analyst attentionFree Investment Community - Newser
JMP reiterates Market Outperform rating on Crinetics stock as paltusotine shows strong data - Investing.com Nigeria
Teacher Retirement System of Texas Sells 1,561 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Reports Durable Symptom, Hormone Control With Oral Drug In Acromegaly - inkl
Crinetics reveals new data from acromegaly therapy programme - Yahoo Finance
New data for oral acromegaly drug ahead of approval decision - The Pharma Letter
Acromegaly's Next Frontier: Crinetics' PALSONIFY Aims to Overhaul Treatment Standards - AInvest
Crinetics Pharmaceuticals New Data Show Durable Control of Palsonify in Acromegaly - MarketScreener
CRNX to Highlight PALSONIFY Data at ENDO 2025 | CRNX Stock News - GuruFocus
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025 - The Manila Times
Crinetics Pharmaceuticals Presents New Long-Term Data on PALSONIFY for Acromegaly at ENDO 2025 - Quiver Quantitative
Breakthrough: Crinetics' Once-Daily Oral PALSONIFY Matches Injectable Treatments in 96-Week Acromegaly Study - Stock Titan
Crinetics to Present New Long-Term Data Demonstrating Durable Co - GuruFocus
Amalgamated Bank Boosts Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
The Goldman Sachs Group Initiates Coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals to Report Second Quarter 2025 Financia - GuruFocus
Crinetics Earnings: Q2 2025 Results and Conference Call Scheduled for August 7 After Market Close - Stock Titan
Goldman Sachs initiates coverage on Crinetics stock with Neutral rating By Investing.com - Investing.com Canada
Crinetics Pharmaceuticals Announces July 2025 Inducement Grants - GuruFocus
4.79%
0.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):